Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | Paul CerroCedar Grove Capital Management | BiotechnologyBiotechnology | Cedar Grove Capital Management - QURE Our biggest contributors of the quarter were The Oncology Institute (TOI), Hims and Hers Health (HIMS), and uniQure NV (QURE). During the quarter,... | BULL | View Pitch → | |
| Sep 2, 2026 | Fund Letter | Hawkins EntrekinWarden Capital | BiotechnologyBiotechnology | Warden Capital - QURE Uniqure is a biotech that has developed a promising treatment for Huntington's disease, a relatively rare, 100% fatal neurodegenerative disease. It published results... | NEUTRAL | View Pitch → | |
| Aug 1, 2026 | Seeking Alpha | Seeking Alpha ContributorSeeking Alpha | BiotechnologyBiotechnology | uniQure N.V. V. is developing AMT-130,... | NEUTRAL | View Pitch → | |
| Feb 3, 2026 | Fund Letter | Hawkins EntrekinWarden Capital | BiotechnologyBiotechnology | Warden Capital 2025 Q4 (QURE) One of those is that I have been ramping up non CRE investments, an interesting example of which is uniQure. This is a... | BULL | View Pitch → | |
| Jan 27, 2026 | Fund Letter | Amy ZhangAlger Small Cap Focus Fund | BiotechnologyBiotechnology | Alger Small Cap Focus Fund 2025 Q4 (QURE) uniQure is a biotechnology company developing AMT-130, an investigational gene therapy for Huntington's disease—an area with no approved disease-modifying treatments. Shares were highly... | BULL | View Pitch → | |
| Jan 20, 2026 | Fund Letter | Daniel BarkerApis Flagship Fund | BiotechnologyBiotechnology | Apis Flagship Fund 2025 Q4 (QURE) UniQure detracted about 1.1% during the quarter. BSD Analysis: uniQure... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.